デフォルト表紙
市場調査レポート
商品コード
1728162

副腎不全市場- 世界の産業規模、シェア、動向、機会、予測、種類別、治療法別、投与経路別、流通チャネル別、地域別、競合別、2020-2030年

Adrenal Insufficiency Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Route of Administration, By Distribution Channel By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
副腎不全市場- 世界の産業規模、シェア、動向、機会、予測、種類別、治療法別、投与経路別、流通チャネル別、地域別、競合別、2020-2030年
出版日: 2025年05月16日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

副腎不全の世界市場は、2024年に3億5,621万米ドルと評価され、2030年までCAGR 8.86％で成長すると予測されています。

副腎不全は、副腎によるコルチゾール産生不全に起因する重篤な内分泌疾患であり、治療しなければ生命を脅かす可能性があります。同市場には、この疾患を管理するための診断ツール、治療介入、支持療法が含まれます。認知度の上昇、診断能力の向上、自己免疫疾患や感染症、長期にわたるグルココルチコイドの使用に関連した発症率の増加が市場拡大に寄与しています。2024年に報告されたように、副腎不全は長期ステロイド治療を受けている患者にしばしば出現し、効果的な治療経路と早期医療介入の必要性を強調しています。このような進化する情勢は、予防および個別化ヘルスケアの両ソリューションに対する世界の旺盛な需要を喚起しています。

市場概要
予測期間 2026-2030
市場規模：2024年 3億5,621万米ドル
市場規模：2030年 5億8,814万米ドル
CAGR：2025年～2030年 8.86%
急成長セグメント グルココルチコイド
最大市場 北米

市場促進要因

副腎不全の普及率上昇

主な市場課題

診断の複雑さ

主要市場動向

遺伝子検査と個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の副腎不全市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別（一次、二次、三次）
    • 治療別（グルココルチコイド、コルチコトロピン、その他）
    • 投与経路別（経口、注射、その他）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 地域別
    • 企業別（2024）
  • 市場マップ
    • タイプ別
    • 治療別
    • 投与経路別
    • 流通チャネル別
    • 地域別

第5章 アジア太平洋地域の副腎不全市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 治療別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第6章 欧州の副腎不全市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第7章 北米の副腎不全市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 南米の副腎不全市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第9章 中東・アフリカの副腎不全市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第12章 世界の副腎不全市場：SWOT分析

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Acrotech Biopharma, Inc.
  • Bausch Health, Canada Inc
  • AdvaCare Pharma
  • Weefselpharma
  • Cipla Inc.
  • Pfizer Inc
  • Wellona Pharma
  • Eugia US
  • Sandoz Inc.
  • Prevego Healthcare & Research Pvt Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17332

The Global Adrenal Insufficiency Market was valued at USD 356.21 million in 2024 and is expected to grow at a CAGR of 8.86% through 2030. Adrenal insufficiency is a serious endocrine disorder resulting from inadequate cortisol production by the adrenal glands, which can be life-threatening if untreated. The market encompasses diagnostic tools, therapeutic interventions, and supportive treatments for managing this condition. A rise in awareness, improved diagnostic capabilities, and growing incidence linked to autoimmune disorders, infections, and prolonged glucocorticoid use are contributing to market expansion. As reported in 2024, adrenal insufficiency often emerges in patients on long-term steroid therapy, underlining the need for effective treatment pathways and early medical intervention. This evolving landscape has sparked robust demand for both preventive and personalized healthcare solutions worldwide.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 356.21 Million
Market Size 2030USD 588.14 Million
CAGR 2025-20308.86%
Fastest Growing SegmentGlucocorticoid
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Adrenal Insufficiency

The growing incidence of adrenal insufficiency is a primary driver of market growth. This chronic condition results from inadequate cortisol production and is frequently associated with autoimmune diseases, prolonged steroid use, and infections that impact adrenal function. According to the National Institutes of Health, adrenal insufficiency now affects an estimated 150 to 280 individuals per million. Rising cases of Addison's disease and secondary adrenal insufficiency linked to pituitary dysfunction are increasing the number of patients requiring diagnosis and long-term hormone replacement therapy. Infections and medication-induced adrenal suppression are also contributing to the growing patient pool, emphasizing the need for accessible and effective treatment solutions.

Key Market Challenges

Diagnostic Complexity

The complexity of diagnosing adrenal insufficiency remains a major barrier to market growth. The condition manifests through diverse symptoms-such as fatigue, hypotension, gastrointestinal discomfort, and psychological disturbances-which often overlap with other medical issues, leading to delayed or missed diagnoses. Differentiating between primary, secondary, and tertiary adrenal insufficiency adds further difficulty due to varied underlying causes, including adrenal gland damage, pituitary malfunction, or hypothalamic dysfunction. Accurate diagnosis requires specific hormonal testing and interpretation, making it reliant on specialized clinical expertise and advanced laboratory infrastructure. These diagnostic challenges limit timely intervention and contribute to underdiagnosis, particularly in resource-constrained healthcare systems.

Key Market Trends

Genetic Testing and Personalized Medicine

The integration of genetic testing and personalized treatment approaches is emerging as a transformative trend in adrenal insufficiency care. Genetic screening enables early identification of hereditary or mutation-related causes of cortisol deficiency, streamlining diagnosis and informing targeted therapeutic strategies. This personalized approach supports better clinical outcomes by customizing glucocorticoid replacement therapies to individual patient needs, optimizing dosing, and minimizing adverse effects. The broader trend toward precision medicine is accelerating the adoption of advanced diagnostics in endocrine disorders, with genetic insights playing a key role in differentiating adrenal insufficiency subtypes and refining long-term treatment plans.

Key Market Players

  • Acrotech Biopharma, Inc.
  • Bausch Health, Canada Inc
  • AdvaCare Pharma
  • Weefselpharma
  • Cipla Inc.
  • Pfizer Inc
  • Wellona Pharma
  • Eugia US
  • Sandoz Inc.
  • Prevego Healthcare & Research Pvt Ltd

Report Scope:

In this report, the Global Adrenal Insufficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Adrenal Insufficiency Market, By Type:

  • Primary
  • Secondary
  • Tertiary

Adrenal Insufficiency Market, By Treatment:

  • Glucocorticoid
  • Corticotropin
  • Others

Adrenal Insufficiency Market, By Route of Administration:

  • Oral
  • Injectables
  • Others

Adrenal Insufficiency Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Adrenal Insufficiency Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adrenal Insufficiency Market.

Available Customizations:

Global Adrenal Insufficiency Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Adrenal Insufficiency Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Primary, Secondary, Tertiary)
    • 4.2.2. By Treatment (Glucocorticoid, Corticotropin, Others)
    • 4.2.3. By Route of Administration (Oral, Injectables, Others)
    • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 4.2.5. By Region
    • 4.2.6. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Treatment
    • 4.3.3. By Route of Administration
    • 4.3.4. By Distribution Channel
    • 4.3.5. By Region

5. Asia Pacific Adrenal Insufficiency Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Treatment
    • 5.2.3. By Route of Administration
    • 5.2.4. By Distribution Channel
    • 5.2.5. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Adrenal Insufficiency Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Treatment
        • 5.3.1.2.3. By Route of Administration
        • 5.3.1.2.4. By Distribution Channel
    • 5.3.2. India Adrenal Insufficiency Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Treatment
        • 5.3.2.2.3. By Route of Administration
        • 5.3.2.2.4. By Distribution Channel
    • 5.3.3. Australia Adrenal Insufficiency Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Treatment
        • 5.3.3.2.3. By Route of Administration
        • 5.3.3.2.4. By Distribution Channel
    • 5.3.4. Japan Adrenal Insufficiency Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Treatment
        • 5.3.4.2.3. By Route of Administration
        • 5.3.4.2.4. By Distribution Channel
    • 5.3.5. South Korea Adrenal Insufficiency Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Treatment
        • 5.3.5.2.3. By Route of Administration
        • 5.3.5.2.4. By Distribution Channel

6. Europe Adrenal Insufficiency Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Adrenal Insufficiency Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Germany Adrenal Insufficiency Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Spain Adrenal Insufficiency Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel
    • 6.3.4. Italy Adrenal Insufficiency Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Treatment
        • 6.3.4.2.3. By Route of Administration
        • 6.3.4.2.4. By Distribution Channel
    • 6.3.5. United Kingdom Adrenal Insufficiency Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Treatment
        • 6.3.5.2.3. By Route of Administration
        • 6.3.5.2.4. By Distribution Channel

7. North America Adrenal Insufficiency Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Route of Administration
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Adrenal Insufficiency Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Mexico Adrenal Insufficiency Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Canada Adrenal Insufficiency Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel

8. South America Adrenal Insufficiency Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Route of Administration
    • 8.2.5. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Adrenal Insufficiency Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Argentina Adrenal Insufficiency Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Colombia Adrenal Insufficiency Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Adrenal Insufficiency Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Adrenal Insufficiency Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Saudi Arabia Adrenal Insufficiency Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. UAE Adrenal Insufficiency Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. Egypt Adrenal Insufficiency Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Treatment
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Adrenal Insufficiency Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Acrotech Biopharma, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Bausch Health, Canada Inc
  • 14.3. AdvaCare Pharma
  • 14.4. Weefselpharma
  • 14.5. Cipla Inc.
  • 14.6. Pfizer Inc
  • 14.7. Wellona Pharma
  • 14.8. Eugia US
  • 14.9. Sandoz Inc.
  • 14.10. Prevego Healthcare & Research Pvt Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer